中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

摄入不同种类的食用油对非酒精性脂肪性肝病的影响

王梓雯 王瑞峰 郭连生 张瑞 徐敏 王小兵

引用本文:
Citation:

摄入不同种类的食用油对非酒精性脂肪性肝病的影响

DOI: 10.3969/j.issn.1001-5256.2021.10.043
基金项目: 

黑龙江省博士后科研启动金 (LBH-Q20033)

详细信息
    通信作者:

    王小兵,wangxiaobing1215@hotmail.com

  • 中图分类号: R575.5

Influence of the intake of different oils on non-alcoholic fatty liver disease

Research funding: 

Heilongjiang Postdoctoral Scientific Research Developmental Fund (LBH-Q20033)

  • 摘要: 目前尚无公认的保肝药物可推荐用于非酒精性脂肪性肝病(NAFLD)常规治疗,其防治手段主要以控制饮食、运动和减肥手术为主。而饮食控制是最基础的干预方式,科学合理的膳食指导尤为重要。简要总结了饮食中常含的几种油类对NAFLD肝脏脂肪变性、炎症、氧化应激等方面的影响,认为鱼油、橄榄油、初榨椰子油及松子油对NAFLD有益,而过量摄入猪油及棕榈油则会加重NAFLD。

     

  • [1] YOUNOSSI ZM. Non-alcoholic fatty liver disease - A global public health perspective[J]. J Hepatol, 2019, 70(3): 531-544. DOI: 10.1016/j.jhep.2018.10.033.
    [2] LOMONACO R, ORTIZ-LOPEZ C, ORSAK B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease[J]. Hepatology, 2012, 55(5): 1389-1397. DOI: 10.1002/hep.25539.
    [3] BYRNE CD, TARGHER G. NAFLD: A multisystem disease[J]. J Hepatol, 2015, 62(1 Suppl): s47-s64. DOI: 10.1016/j.jhep.2014.12.012.
    [4] FRIEDMAN SL, NEUSCHWANDER-TETRI BA, RINELLA M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922. DOI: 10.1038/s41591-018-0104-9.
    [5] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [6] MACIEJEWSKA D, MARLICZ W, RYTERSKA K, et al. Changes of the fatty acid profile in erythrocyte membranes of patients following 6-month dietary intervention aimed at the regression of nonalcoholic fatty liver disease (NAFLD)[J]. Can J Gastroenterol Hepatol, 2018, 2018: 5856201. DOI: 10.1155/2018/5856201.
    [7] ORSAVOVA J, MISURCOVA L, AMBROZOVA JV, et al. Fatty acids composition of vegetable oils and its contribution to dietary energy intake and dependence of cardiovascular mortality on dietary intake of fatty acids[J]. Int J Mol Sci, 2015, 16(6): 12871-12890. DOI: 10.3390/ijms160612871.
    [8] MUSSO G, GAMBINO R, DE MICHIELI F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis[J]. Hepatology, 2003, 37(4): 909-916. DOI: 10.1053/jhep.2003.50132.
    [9] BERNÁ G, ROMERO-GOMEZ M. The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management[J]. Liver Int, 2020, 40 Suppl 1: 102-108. DOI: 10.1111/liv.14360.
    [10] GEPNER Y, SHELEF I, KOMY O, et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content[J]. J Hepatol, 2019, 71(2): 379-388. DOI: 10.1016/j.jhep.2019.04.013.
    [11] JUMP DB, LYTLE KA, DEPNER CM, et al. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease[J]. Pharmacol Ther, 2018, 181: 108-125. DOI: 10.1016/j.pharmthera.2017.07.007.
    [12] HODSON L, BHATIA L, SCORLETTI E, et al. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: A pilot study[J]. Eur J Clin Nutr, 2017, 71(10): 1251. DOI: 10.1038/ejcn.2017.145.
    [13] SPAHIS S, ALVAREZ F, AHMED N, et al. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: Impact of omega-3 fatty acids[J]. J Nutr Biochem, 2018, 58: 28-36. DOI: 10.1016/j.jnutbio.2018.03.025.
    [14] TOBIN D, BREVIK-ANDERSEN M, QIN Y, et al. Evaluation of a high concentrate Omega-3 for correcting the Omega-3 fatty acid nutritional deficiency in non-alcoholic fatty liver disease (CONDIN)[J]. Nutrients, 2018, 10(8). DOI: 10.3390/nu10081126.
    [15] OKADA L, OLIVEIRA CP, STEFANO JT, et al. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight[J]. Clin Nutr, 2018, 37(5): 1474-1484. DOI: 10.1016/j.clnu.2017.08.031.
    [16] HARARI A, LEIKIN FRENKEL A, BARSHACK I, et al. Addition of fish oil to atherogenic high fat diet inhibited atherogenesis while olive oil did not, in LDL receptor KO mice[J]. Nutr Metab Cardiovasc Dis, 2020, 30(4): 709-716. DOI: 10.1016/j.numecd.2019.12.007.
    [17] LIONETTI L, MOLLICA MP, DONIZZETTI I, et al. High-lard and high-fish-oil diets differ in their effects on function and dynamic behaviour of rat hepatic mitochondria[J]. PLoS One, 2014, 9(3): e92753. DOI: 10.1371/journal.pone.0092753.
    [18] REZAEI S, AKHLAGHI M, SASANI MR, et al. Olive oil lessened fatty liver severity independent of cardiometabolic correction in patients with non-alcoholic fatty liver disease: A randomized clinical trial[J]. Nutrition, 2019, 57: 154-161. DOI: 10.1016/j.nut.2018.02.021.
    [19] TUCK KL, HAYBALL PJ. Major phenolic compounds in olive oil: Metabolism and health effects[J]. J Nutr Biochem, 2002, 13(11): 636-644. DOI: 10.1016/s0955-2863(02)00229-2.
    [20] ECHEVERRÍA F, ORTIZ M, VALENZUELA R, et al. Hydroxytyrosol and cytoprotection: A projection for clinical interventions[J]. Int J Mol Sci, 2017, 18(5): 930. DOI: 10.3390/ijms18050930.
    [21] NOBILI V, ALISI A, MOSCA A, et al. The antioxidant effects of hydroxytyrosol and vitamin E on pediatric nonalcoholic fatty liver disease, in a clinical trial: A new treatment?[J]. Antioxid Redox Signal, 2019, 31(2): 127-133. DOI: 10.1089/ars.2018.7704.
    [22] GORI M, GIANNITELLI SM, ZANCLA A, et al. Quercetin and hydroxytyrosol as modulators of hepatic steatosis: A NAFLD-on-a-chip study[J]. Biotechnol Bioeng, 2021, 118(1): 142-152. DOI: 10.1002/bit.27557.
    [23] DONG YZ, LI L, ESPE M, et al. Hydroxytyrosol attenuates hepatic fat accumulation via activating mitochondrial biogenesis and autophagy through the AMPK pathway[J]. J Agric Food Chem, 2020, 68(35): 9377-9386. DOI: 10.1021/acs.jafc.0c03310.
    [24] CHEN X, LI L, LIU X, et al. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis[J]. Life Sci, 2018, 203: 291-304. DOI: 10.1016/j.lfs.2018.04.022.
    [25] PERDOMO CM, FRVHBECK G, ESCALADA J. Impact of nutritional changes on nonalcoholic fatty liver disease[J]. Nutrients, 2019, 11(3): 677. DOI: 10.3390/nu11030677.
    [26] DJOHAN YF, BADIA E, BONAFOS B, et al. High dietary intake of palm oils compromises glucose tolerance whereas high dietary intake of olive oil compromises liver lipid metabolism and integrity[J]. Eur J Nutr, 2019, 58(8): 3091-3107. DOI: 10.1007/s00394-018-1854-3.
    [27] FUCHS M, SANYAL AJ. Lipotoxicity in NASH[J]. J Hepatol, 2012, 56(1): 291-293. DOI: 10.1016/j.jhep.2011.05.019.
    [28] ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40(12): 1461-1465. DOI: 10.1038/ng.257.
    [29] HOEKSTRA M, LI Z, KRUIJT JK, et al. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status[J]. J Hepatol, 2010, 52(2): 244-251. DOI: 10.1016/j.jhep.2009.11.004.
    [30] PERNAS L, SCORRANO L. Mito-morphosis: Mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function[J]. Annu Rev Physiol, 2016, 78: 505-531. DOI: 10.1146/annurev-physiol-021115-105011.
    [31] ZHU W, FENG PP, HE K, et al. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet[J]. Biochem Biophys Res Commun, 2018, 505(2): 523-529. DOI: 10.1016/j.bbrc.2018.09.134.
    [32] SALES RC, MEDEIROS PC, SPREAFICO F, et al. Olive oil, palm oil, and hybrid palm oil distinctly modulate liver transcriptome and induce NAFLD in mice fed a high-fat diet[J]. Int J Mol Sci, 2018, 20(1): 8. DOI: 10.3390/ijms20010008.
    [33] RONIS MJ, BAUMGARDNER JN, SHARMA N, et al. Medium chain triglycerides dose-dependently prevent liver pathology in a rat model of non-alcoholic fatty liver disease[J]. Exp Biol Med (Maywood), 2013, 238(2): 151-162. DOI: 10.1258/ebm.2012.012303.
    [34] DELANY JP, WINDHAUSER MM, CHAMPAGNE CM, et al. Differential oxidation of individual dietary fatty acids in humans[J]. Am J Clin Nutr, 2000, 72(4): 905-911. DOI: 10.1093/ajcn/72.4.905.
    [35] ARUNIMA S, RAJAMOHAN T. Influence of virgin coconut oil-enriched diet on the transcriptional regulation of fatty acid synthesis and oxidation in rats - a comparative study[J]. Br J Nutr, 2014, 111(10): 1782-1790. DOI: 10.1017/S000711451400004X.
    [36] NARAYANANKUTTY A, PALLIYIL DM, KURUVILLA K, et al. Virgin coconut oil reverses hepatic steatosis by restoring redox homeostasis and lipid metabolism in male Wistar rats[J]. J Sci Food Agric, 2018, 98(5): 1757-1764. DOI: 10.1002/jsfa.8650.
    [37] HU T, FOXWORTHY P, SIESKY A, et al. Hepatic peroxisomal fatty acid beta-oxidation is regulated by liver X receptor alpha[J]. Endocrinology, 2005, 146(12): 5380-5387. DOI: 10.1210/en.2005-0591.
    [38] ADEYEMI WJ, OLAYAKI LA, ABDUSSALAM TA, et al. Investigation of the effects of dietary modification in experimental obesity: Low dose of virgin coconut oil has a potent therapeutic value[J]. Biomed Pharmacother, 2020, 126: 110110. DOI: 10.1016/j.biopha.2020.110110.
    [39] PARK S, SHIN S, LIM Y, et al. Korean pine nut oil attenuated hepatic triacylglycerol accumulation in high-fat diet-induced obese mice[J]. Nutrients, 2016, 8(1): 59. DOI: 10.3390/nu8010059.
    [40] LEE AR, HAN SN. Pinolenic acid downregulates lipid anabolic pathway in HepG2 cells[J]. Lipids, 2016, 51(7): 847-855. DOI: 10.1007/s11745-016-4149-6.
    [41] ZHANG J, ZHANG SD, WANG P, et al. Pinolenic acid ameliorates oleic acid-induced lipogenesis and oxidative stress via AMPK/SIRT1 signaling pathway in HepG2 cells[J]. Eur J Pharmacol, 2019, 861: 172618. DOI: 10.1016/j.ejphar.2019.172618.
    [42] TARGHER G, BYRNE CD, LONARDO A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis[J]. J Hepatol, 2016, 65(3): 589-600. DOI: 10.1016/j.jhep.2016.05.013.
    [43] BYRNE CD, TARGHER G. NAFLD as a driver of chronic kidney disease[J]. J Hepatol, 2020, 72(4): 785-801. DOI: 10.1016/j.jhep.2020.01.013.
    [44] KIM GA, LEE HC, CHOE J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate[J]. J Hepatol, 2017. DOI: 10.1016/j.jhep.2017.09.012.[Online ahead of print]
  • 加载中
计量
  • 文章访问数:  328
  • HTML全文浏览量:  106
  • PDF下载量:  44
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-03-11
  • 录用日期:  2021-05-06
  • 出版日期:  2021-10-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回